دورية أكاديمية
Optimizing next-generation RSV prevention in Mali: A cost-effectiveness analysis of pediatric vaccination, maternal vaccination, and extended half-life monoclonal antibody immunoprophylaxis.
| العنوان: | Optimizing next-generation RSV prevention in Mali: A cost-effectiveness analysis of pediatric vaccination, maternal vaccination, and extended half-life monoclonal antibody immunoprophylaxis. |
|---|---|
| المؤلفون: | Laufer RS; Center for Vaccine Development & Global Health, University of Maryland School of Medicine, Baltimore, MD, United States of America., Baral R; PATH, Seattle, WA, United States of America., Buchwald AG; Center for Vaccine Development & Global Health, University of Maryland School of Medicine, Baltimore, MD, United States of America., Campbell JD; Department of Pediatrics, Center for Vaccine Development & Global Health, University of Maryland School of Medicine, Baltimore, MD, United States of America., Coulibaly F; Centre pour le Développement des Vaccins, Ministère de la Santé, Bamako, Mali., Diallo F; Centre pour le Développement des Vaccins, Ministère de la Santé, Bamako, Mali., Doumbia M; Centre pour le Développement des Vaccins, Ministère de la Santé, Bamako, Mali., Driscoll AJ; Center for Vaccine Development & Global Health, University of Maryland School of Medicine, Baltimore, MD, United States of America., Galvani AP; Center for Infectious Disease Modeling and Analysis, Yale School of Public Health, New Haven, CT, United States of America., Keita AM; Centre pour le Développement des Vaccins, Ministère de la Santé, Bamako, Mali., Neuzil KM; Center for Vaccine Development & Global Health, University of Maryland School of Medicine, Baltimore, MD, United States of America., Sow S; Centre pour le Développement des Vaccins, Ministère de la Santé, Bamako, Mali., Pecenka C; PATH, Seattle, WA, United States of America., Ortiz JR; Center for Vaccine Development & Global Health, University of Maryland School of Medicine, Baltimore, MD, United States of America., Fitzpatrick MC; Center for Vaccine Development & Global Health, University of Maryland School of Medicine, Baltimore, MD, United States of America. |
| المصدر: | PLOS global public health [PLOS Glob Public Health] 2023 May 05; Vol. 3 (5), pp. e0001432. Date of Electronic Publication: 2023 May 05 (Print Publication: 2023). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Public Library of Science Country of Publication: United States NLM ID: 9918283779606676 Publication Model: eCollection Cited Medium: Internet ISSN: 2767-3375 (Electronic) Linking ISSN: 27673375 NLM ISO Abbreviation: PLOS Glob Public Health Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: San Francisco, California : Public Library of Science, [2021]- |
| مستخلص: | Respiratory syncytial virus (RSV) is the most common cause of early childhood lower respiratory tract infection (LRTI) in low- and middle-income countries (LMICs). Maternal vaccines, birth-dose extended half-life monoclonal antibodies (mAbs), and pediatric vaccines are under development for prevention of respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) in young children. We analyzed the health and economic impact of RSV interventions used alone or in combinations in Mali. We modeled age-specific and season-specific risks of RSV LRTI in children through three years, using WHO Preferred Product Characteristics and data generated in Mali. Health outcomes included RSV LRTI cases, hospitalizations, deaths, and disability-adjusted life-years (DALYs). We identified the optimal combination of products across a range of scenarios. We found that mAb delivered at birth could avert 878 DALYs per birth cohort at an incremental cost-effectiveness ratio (ICER) of $597 per DALY averted compared to no intervention if the product were available at $1 per dose. Combining mAb with pediatric vaccine administered at 10/14 weeks, 1947 DALYs would be prevented. The ICER of this combination strategy is $1514 per DALY averted compared to mAb alone. Incorporating parameter uncertainty, mAb alone is likely to be optimal from the societal perspective at efficacy against RSV LRTI above 66%. The optimal strategy was sensitive to economic considerations, including product prices and willingness-to-pay for DALYs. For example, the combination of mAb and pediatric vaccine would be optimal from the government perspective at a willingness-to-pay above $775 per DALY. Maternal vaccine alone or in combination with other interventions was never the optimal strategy, even for high vaccine efficacy. The same was true for pediatric vaccine administered at 6/7 months. At prices comparable to existing vaccine products, extended half-life RSV mAbs would be impactful and efficient components of prevention strategies in LMICs such as Mali. Competing Interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: • Rachel S. Laufer reports no interests. • Ranju Baral reports that her institution has received research grants from the Bill and Melinda Gates Foundation. • Andrea G. Buchwald reports no interests. • James D. Campbell reports that his institution has received research grants from GlaxoSmithKline and Pfizer. • Flanon Coulibaly reports no interests. • Fatoumata Diallo reports no interests. • Moussa Doumbia reports no interests. • Amanda J. Driscoll reports no interests. • Alison P. Galvani reports no interests. • Adama M. Keita reports no interests. • Kathleen M. Neuzil reports that her institution has received research grants from GlaxoSmithKline, Pfizer, PATH, and National Institutes of Health for vaccine research. She is a member of SAGE. • Clint Pecenka reports that his institution has received research grants from the Bill and Melinda Gates Foundation. • Samba Sow reports no interests. • Justin R. Ortiz reports grants to his institution from National Science Foundation, Bill & Melinda Gates Foundation, Pfizer, National Institutes of Health, and World Health Organization outside the submitted work. • Meagan C. Fitzpatrick reports personal fees from Sanofi Pasteur, outside the submitted work. (Copyright: © 2023 Laufer et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.) |
| References: | Clin Infect Dis. 2020 Jan 1;70(1):59-66. (PMID: 30810160) MMWR Recomm Rep. 2022 Aug 26;71(1):1-28. (PMID: 36006864) Vaccine. 2003 Jul 28;21(24):3389-92. (PMID: 12850346) PLoS One. 2017 Feb 7;12(2):e0171499. (PMID: 28170416) N Engl J Med. 2022 Mar 3;386(9):837-846. (PMID: 35235726) Lancet. 2019 Aug 31;394(10200):757-779. (PMID: 31257127) PLoS Med. 2017 Oct 2;14(10):e1002397. (PMID: 28968399) Lancet. 2018 Nov 10;392(10159):1789-1858. (PMID: 30496104) Pharmacoeconomics. 2014 Jun;32(6):525-31. (PMID: 24791735) Rev Infect Dis. 1983 Jul-Aug;5(4):758-64. (PMID: 6353530) BMC Med. 2020 Apr 6;18(1):82. (PMID: 32248817) Pediatrics. 2005 Jul;116(1):153-9. (PMID: 15995046) Clin Dev Immunol. 2012;2012:985646. (PMID: 22235228) Euro Surveill. 2021 Apr;26(17):. (PMID: 33928899) Value Health. 2021 Jan;24(1):61-66. (PMID: 33431154) PLoS One. 2021 Jan 11;16(1):e0244995. (PMID: 33428635) Lancet. 2022 May 28;399(10340):2047-2064. (PMID: 35598608) Med Decis Making. 1998 Apr-Jun;18(2 Suppl):S68-80. (PMID: 9566468) Vaccine. 2020 Jul 14;38(33):5268-5277. (PMID: 32586763) Vaccines (Basel). 2021 Aug 28;9(9):. (PMID: 34579198) Vaccine. 2022 Jun 9;40(26):3506-3510. (PMID: 35184927) Vaccine. 2016 Jun 3;34(26):2870-2875. (PMID: 27105562) Ann Intern Med. 2014 Jan 21;160(2):91-100. (PMID: 24592494) Vaccine. 2021 Aug 16;39(35):5037-5045. (PMID: 34325934) Lancet. 2017 Sep 2;390(10098):946-958. (PMID: 28689664) Lancet Infect Dis. 2016 Sep;16(9):1026-1035. (PMID: 27261067) BMJ Open. 2021 Apr 24;11(4):e046563. (PMID: 33895717) |
| معلومات مُعتمدة: | T32 AI007524 United States AI NIAID NIH HHS |
| تواريخ الأحداث: | Date Created: 20230505 Latest Revision: 20231031 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC10162555 |
| DOI: | 10.1371/journal.pgph.0001432 |
| PMID: | 37145993 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2767-3375 |
|---|---|
| DOI: | 10.1371/journal.pgph.0001432 |